Olaparib: all 338 studies that test it

Page 4 of 4. Open to participants first (61), then studies with results posted, then the rest; newest registration first within each.

• Platine, Avastin and OLAparib in 1st LineCompletedNCT02477644Phase 3
• Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior ChemotherapyStatus unknownNCT02446704Phase 1/2
• Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced CancerCompletedNCT02418624Phase 1
• Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)CompletedNCT02398058Phase 1
• Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes MutationsWithdrawnNCT02392676Phase 3
• A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on OlaparibCompletedNCT02340611Phase 2
• Trial of Olaparib in Combination with AZD5363 (ComPAKT)CompletedNCT02338622Phase 1
• Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck CancerCompletedNCT02308072Phase 1
• SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerActive, not recruitingNCT02299999Phase 2
• Olaparib and Radiotherapy in Head and Neck CancerActive, not recruitingNCT02229656Phase 1
• Olaparib and Radiotherapy in Inoperable Breast CancerCompletedNCT02227082Phase 1
• Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube CancerCompletedNCT02121990Phase 1
• SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC PatientsCompletedNCT02117167Phase 2
• To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid TumoursCompletedNCT01921140Phase 1
• D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid TumoursCompletedNCT01851265Phase 1
• Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN)Status unknownNCT01788332Phase 2
• TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate CancerStatus unknownNCT01682772Phase 2
• Olaparib for Patients With Recurrent BRCA Deficient Ovarian CancerWithdrawnNCT01661868Phase 2
• Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian CancerStatus unknownNCT01650376Phase 1/2
• Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian CancerCompletedNCT01623349Phase 1
• Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLCCompletedNCT01562210Phase 1
• Phase I Study of Olaparib With Cisplatin Based Chemoradiotherapy in Squamous Cell Carcinoma of the Head and NeckWithdrawnNCT01491139Phase 1
• Radiotherapy & Olaparib in COmbination for Carcinoma of the OesophagusStatus unknownNCT01460888Phase 1
• AZD2281 Plus Carboplatin to Treat Breast and Ovarian CancerCompletedNCT01445418Phase 1
• Olaparib and Temozolomide in Treating Patients With Relapsed GlioblastomaCompletedNCT01390571Phase 1
• Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s CancersCompletedNCT01237067Phase 1
• AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid TumoursTerminatedNCT00819221Phase 1
• Phase I AZD2281/Cisplatin in Advanced Solid Tumour PatientsCompletedNCT00782574Phase 1
• Phase I Comparative Bioavailability StudyActive, not recruitingNCT00777582Phase 1
• Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid TumoursCompletedNCT00710268Phase 1
• Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast CancerCompletedNCT00707707Phase 1
• AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor CancersCompletedNCT00678132Phase 1
• Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic TumoursCompletedNCT00633269Phase 1
• Open Label, Dose Escalation Phase I Study of AZD2281CompletedNCT00572364Phase 1
• A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With DacarbazineCompletedNCT00516802Phase 1
• Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With TopotecanCompletedNCT00516438Phase 1
• A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)CompletedNCT00516373Phase 1
• Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic CancerCompletedNCT00515866Phase 1

← Olaparib overview